Posts Tagged ‘Medicine by Design’

Right Turn: Synthetic biology predicted to become a huge industry

Author: Stacey Johnson, 02/10/17

There is a trend in the regenerative medicine field to include gene therapies when describing the work being performed by academics and industry, as in “cell and gene therapies.” The wider definition better reflects how the industry is evolving and acknowledges the dual focus. I expect the same may happen with synthetic biology’s role in…Read more

Peter Zandstra and CCRM: Making cell therapies a commercial reality

Author: Guest, 01/31/17

Dr. Rohin Iyer is currently a Development Manager at GE Healthcare / CCRM. He did his PhD in Biomedical Engineering at the University of Toronto, and has been working in the field of stem cells and tissue engineering for over 12 years. He is an avid tweeter (follow @DrRohinIyer) on cell therapies and regenerative medicine. …Read more

Can we use animals as living incubators for human tissue?

Author: Jovana Drinjakovic, 01/16/17

Markus Grompe certainly thinks so and is working hard to make it happen. A scientist and a pediatrician specializing in inborn liver diseases, Dr. Grompe has a plan for overcoming the shortage of organ donors—the key obstacle for patients for whom the liver transplant is the only hope. Based at the Oregon Health and Science…Read more

Inaugural Medicine by Design Symposium – Engineering progress in regenerative medicine

Author: Nicole Forgione, 12/21/16

On November 28 local and international leaders of the regenerative medicine (RM) community gathered at the MaRS Centre in Toronto for the first ever Medicine by Design (MbD) Symposium. The event marked the first year of the MbD program at the University of Toronto (U of T). This initiative was established based on a $114…Read more

Special op/ed: Canada can lead the world in regenerative medicine — but it won’t happen without strategic investment

Author: Michael May, 08/30/16

Michael May is President and CEO of CCRM, a leader in developing and commercializing regenerative medicine, cell and gene therapy technologies, Michael Rudnicki is Scientific Director and CEO of Stem Cell Network, with a mandate to translate stem cell research into clinical applications, commercial products and public policy, and Peter Zandstra is a professor in…Read more